According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia.

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

The approval in previously treated pediatric patients was based on data from the Alfa-PROTECT and PROTECT Kids studies.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

No gynecological malignancies were seen, while expected incidence was 0.26 or greater for all cancer types. HealthDay News — Short-term testosterone use among transmasculine and gender diverse ...

Scientists from Children’s Hospital of Philadelphia, Penn Medicine and other partners created a therapy that targeted KJ’s specific genetic mutation. HealthDay News — A baby born with a rare ...

"As policymakers debate whether to enact drastic cuts to Medicaid funding, they should consider the possibility that doing so could similarly disrupt chronic disease therapy for children.